These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 22670911)

  • 1. Discontinuing donepezil or starting memantine for Alzheimer's disease.
    Suzuki T
    N Engl J Med; 2012 Jun; 366(23):2227-8; author reply 2228. PubMed ID: 22670911
    [No Abstract]   [Full Text] [Related]  

  • 2. Discontinuing donepezil or starting memantine for Alzheimer's disease.
    Schneider LS
    N Engl J Med; 2012 Mar; 366(10):957-9. PubMed ID: 22397659
    [No Abstract]   [Full Text] [Related]  

  • 3. Discontinuing donepezil or starting memantine for Alzheimer's disease.
    Finucane MM; Finucane TE
    N Engl J Med; 2012 Jun; 366(23):2227-8; author reply 2228. PubMed ID: 22670912
    [No Abstract]   [Full Text] [Related]  

  • 4. Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine.
    Tariot PN
    Evid Based Med; 2013 Apr; 18(2):62-3. PubMed ID: 22736656
    [No Abstract]   [Full Text] [Related]  

  • 5. New drugs for Alzheimer's disease in Japan.
    Takeda M; Tanaka T; Okochi M
    Psychiatry Clin Neurosci; 2011 Aug; 65(5):399-404. PubMed ID: 21851448
    [No Abstract]   [Full Text] [Related]  

  • 6. Donepezil and memantine for moderate-to-severe Alzheimer's disease.
    Howard R; McShane R; Lindesay J; Ritchie C; Baldwin A; Barber R; Burns A; Dening T; Findlay D; Holmes C; Hughes A; Jacoby R; Jones R; Jones R; McKeith I; Macharouthu A; O'Brien J; Passmore P; Sheehan B; Juszczak E; Katona C; Hills R; Knapp M; Ballard C; Brown R; Banerjee S; Onions C; Griffin M; Adams J; Gray R; Johnson T; Bentham P; Phillips P
    N Engl J Med; 2012 Mar; 366(10):893-903. PubMed ID: 22397651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Memantine brakes Alzheimer's dementia. The NMDA antagonist is effective in severe cases, too].
    MMW Fortschr Med; 2003 May; 145 Suppl 2():21. PubMed ID: 14579479
    [No Abstract]   [Full Text] [Related]  

  • 8. Memantine for patients with Alzheimer disease.
    Finucane TE
    JAMA; 2004 Apr; 291(14):1695; author reply 1695. PubMed ID: 15082684
    [No Abstract]   [Full Text] [Related]  

  • 9. UK government guidance on Alzheimer's drugs postponed.
    O'Neill MF
    Drug Discov Today; 2005 Sep; 10(17):1132. PubMed ID: 16182201
    [No Abstract]   [Full Text] [Related]  

  • 10. [Advances in Alzheimer's disease treatment].
    Nourhashémi F
    Rev Med Interne; 2006 Aug; 27(8):585-7. PubMed ID: 16782240
    [No Abstract]   [Full Text] [Related]  

  • 11. Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease.
    Waldemar G; Hyvärinen M; Josiassen MK; Kørner A; Lehto H; Wetterberg P
    Int J Geriatr Psychiatry; 2008 Sep; 23(9):979-81. PubMed ID: 18229874
    [No Abstract]   [Full Text] [Related]  

  • 12. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
    Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
    JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's disease: will advances made in the past turn the tide?
    Semla TP
    Ann Pharmacother; 2007 Sep; 41(9):1494-6. PubMed ID: 17666576
    [No Abstract]   [Full Text] [Related]  

  • 14. Memantine is associated with longer survival than donepezil in a Veterans Affairs prescription database, 1997 to 2008.
    Lazzeroni LC; Halbauer JD; Ashford JW; Noda A; Hernandez B; Azor V; Hozack N; Hasson N; Henderson VW; Yesavage JA; Tinklenberg JR
    J Alzheimers Dis; 2013; 36(4):791-8. PubMed ID: 23703151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Memantine (Ebixa), glutaminergic modulator].
    Sternon J; Bier JC
    Rev Med Brux; 2004 Apr; 25(2):93-7. PubMed ID: 15157062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mechanisms of action of Alzheimer medications].
    Alhainen K
    Duodecim; 2003; 119(20):1959-66. PubMed ID: 14640001
    [No Abstract]   [Full Text] [Related]  

  • 17. Combination therapy no advantage in Alzheimer's treatment.
    Harv Health Lett; 2012 Jun; 37(8):8. PubMed ID: 22774260
    [No Abstract]   [Full Text] [Related]  

  • 18. Combination drug therapies for AD: progress is slow, but we must keep trying.
    Farlow MR
    Geriatrics; 2005 Jun; 60(6):13-4. PubMed ID: 15948660
    [No Abstract]   [Full Text] [Related]  

  • 19. Rationalizing therapeutic approaches in Alzheimer's disease.
    Grossberg GT
    CNS Spectr; 2005 Nov; 10(11 Suppl 18):17-21. PubMed ID: 16273026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).
    Knapp M; King D; Romeo R; Adams J; Baldwin A; Ballard C; Banerjee S; Barber R; Bentham P; Brown RG; Burns A; Dening T; Findlay D; Holmes C; Johnson T; Jones R; Katona C; Lindesay J; Macharouthu A; McKeith I; McShane R; O'Brien JT; Phillips PPJ; Sheehan B; Howard R
    Int J Geriatr Psychiatry; 2017 Dec; 32(12):1205-1216. PubMed ID: 27739182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.